Commercialisation
At a glance

The Institute of Cancer Research, London, is committed to carrying out excellent research and exploiting it to its maximum potential for the benefit of people with cancer. We see partnering with industry as an essential part of our mission since in many cases it is the only way to take our discoveries to patients.

Our innovation success

Our Business and Innovation Office works with commercial partners who can provide the resources and complementary expertise we need to take our research findings through development and make them available to patients.

The primary aim of our collaboration with industry is to ensure the products of our research can be developed for the benefit of cancer patients and their carers. However, we also aim to achieve a fair financial return from the product of our research.

In the 2021/22 academic year The Institute of Cancer Research (ICR) received more than £38 million in royalty income.

Invention income accounted for 24 per cent of our total income in 2021/22.

The ICR, was the most successful higher education institution in the United Kingdom in 2020/21 at earning invention income from its research per member of research staff.

We drive national and international innovation through forming partnerships of different types with a range of different types of company, from major strategic drug discovery partnerships with large companies like Merck, to leading multicentre trials of pharma-owned drugs, and forming partnerships to develop innovative new cancer drugs with smaller biotech companies like Ellipses Pharma and Nuvectis.

Our discoveries

Since 2005, the ICR has discovered 21 drug candidates. We have successfully progressed 13 drugs into clinical trials, in collaboration with industry partners.

More than 500,000 men have been treated with abiraterone, which was discovered and initially developed at the ICR. It was ultimately licensed to Janssen Pharmaceutical Company, which has reported billions of dollars in sales. Janssen reported worldwide sales of abiraterone of £1.6 billion (US $1.96 billion) for the year 2022.

We ranked first in the UK for the proportion of papers published with industry co-authors, and first in the world for percentage of publications cited in patents, in recent assessments from the influential U-Multirank.